{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:00:43Z","timestamp":1777438843590,"version":"3.51.4"},"reference-count":72,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Astellas Pharma Inc. Astellas Pharma","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2020,6,12]]},"DOI":"10.1080\/14656566.2020.1739649","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T08:02:27Z","timestamp":1588147347000},"page":"1015-1025","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":33,"title":["Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2193-8327","authenticated-orcid":false,"given":"Hiroyuki","family":"Izutsu","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc., Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31472-1"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1472358"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102822"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040226"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.05.044"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130767"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.854771"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202576"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1002\/art.11096"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.037929"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu430"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvv069"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200595"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1241237"},{"key":"cit0017","doi-asserted-by":"crossref","unstructured":"Tanaka Y. The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases? Rheumatology (Oxford). 2019;58(Suppl 1):i1\u20133.","DOI":"10.1093\/rheumatology\/key280"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0097-3"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000898"},{"key":"cit0020","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) Japan. Smyraf tablets\u00ae 50 mg and 100 mg: interview form v5 2020. [cited 2020 Feb 21]. https:\/\/www.info.pmda.go.jp\/go\/interview\/1\/800126_3999046F1023_1_005_1F.pdf"},{"key":"cit0021","unstructured":"Ministry of Food and Drug Safety Korea. Drug details: 50 mg Smyraf (peficitinib hydrobromide) 2020. [cited 2020 Feb 18]. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetail?itemSeq=202000404"},{"key":"cit0022","unstructured":"Ministry of Food and Drug Safety Korea. Drug details: 100 mg Smyraf (peficitinib hydrobromide) 2020. [cited 2020 Feb 18]. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetail?itemSeq=202000403"},{"key":"cit0023","unstructured":"AbbVie Inc. RINVOQTM (upadacitinib) extended-release tablets: prescribing information 2019. [cited 2019 Oct 10]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211675s000lbl.pdf"},{"key":"cit0024","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) Japan. Deliberation result report: upadacitinib hydrate 7.5 mg, 15 mg. 2019 [cited 2020 Feb 3]. http:\/\/www.pmda.go.jp\/drugs\/2020\/P20200120001\/112130000_30200AMX00027_A100_1.pdf"},{"key":"cit0025","unstructured":"European Medicines Agency (EMA). Assessment Report: Rinvoq (upadacitinib). 2019. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/Rinvoq-epar-public-assessment-report_en.pdf"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0178"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key256"},{"key":"cit0028","unstructured":"U.S. Food and Drug Administration. XELJANZ\u00ae (tofacitinib) tablets: prescribing information. 2018 [cited 2019 Oct 8]. http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=959"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2016.12.001"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"cit0031","author":"Bird P","journal-title":"J Clin Rheumatol"},{"key":"cit0032","unstructured":"European Medicines Agency (EMA). Olumiant EPAR - product information. 2017 [cited 2019 Feb 24]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1608821"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902819"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4221-0"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208279"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215163"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215164"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-2125-2"},{"key":"cit0040","unstructured":"Astellas Pharma China Inc. A study to assess safety and efficacy of ASP015K in patients with rheumatoid arthritis (RA) who had an inadequate response or intolerance to methotrexate (MTX) (NCT03660059). 2019 [cited 2020 Feb 18]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03660059"},{"key":"cit0041","unstructured":"Astellas Pharma Inc. A study to continue ASP015K treatment to rheumatoid arthritis patients who completed phase IIb study or phase III study of ASP015K (NCT01638013). 2019. [cited 2020 Feb 18]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01638013"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key339"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"cit0047","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/annrheumdis-2018-214261","volume":"78","author":"Combe B","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"cit0049","first-page":"259","volume":"78","author":"Westhovens R","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"cit0050","unstructured":"Gilead Sciences Inc. European Medicines Agency validates Marketing Application for filgotinib for the treatment of rheumatoid arthritis. 2019 [cited 2020 Apr 16]. http:\/\/investors.gilead.com\/news-releases\/news-release-details\/european-medicines-agency-validates-marketing-application."},{"key":"cit0051","unstructured":"Gilead Sciences Inc. Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis. n.d. [cited 2019 Oct 24]. http:\/\/investors.gilead.com\/news-releases\/news-release-details\/gilead-and-galapagos-announce-efficacy-and-safety-results"},{"key":"cit0052","first-page":"147","author":"Bechman K","year":"2019","journal-title":"Pharmacol Res"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2018.08.005"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20122760"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.273"},{"key":"cit0056","unstructured":"Astellas Pharma Inc. Peficitinib Common Technical Document - summary of clinical pharmacology studies. [cited 2019 Oct 3]. http:\/\/www.pmda.go.jp\/drugs\/2019\/P20190419003\/index.html"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1026864"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.2685"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.344"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0474-4"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00873-7"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.751"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1002\/art.39955"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1002\/art.40054"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00167-6"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0651-5"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.183"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01131-y"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13748"},{"key":"cit0071","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) Japan. Deliberation result report: Shingrix\u00ae vaccine 2018 [cited 2020 Feb 18]. http:\/\/www.pmda.go.jp\/drugs\/2018\/P20180329002\/342275000_23000AMX00460_A100_1.pdf"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60460-8"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2020.1739649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T09:25:20Z","timestamp":1620465920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2020.1739649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,6,12]]}},"alternative-id":["10.1080\/14656566.2020.1739649"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2020.1739649","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}